Skip to main content
Journal cover image

Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.

Publication ,  Journal Article
Moseley, RP; Papanastassiou, V; Zalutsky, MR; Ashpole, RD; Evans, S; Bigner, DD; Kemshead, JT
Published in: Int J Cancer
August 19, 1992

Ten patients with neoplastic meningitis were treated with a variety of 131I-monoclonal antibody (MAb) conjugates, chosen to bind to their particular malignancy. Pharmacokinetic studies revealed that MAbs leave the ventricular compartment, enter the sub-arachnoid space and then pass into the blood. Once the MAbs enter the blood compartment, their clearance is determined by factors such as circulating anti-mouse Ig and circulating antigens. These lead to complex formations and the clearance of the conjugate by the reticuloendothelial system. In one individual, the anti-mouse Ig response observed systemically was not mirrored within the CSF, which has implications for planning future therapy of this type. In other patients, formation of immune complexes was due to binding to circulating antigen within the blood. The major toxicity associated with the intrathecal administration of 131I-MAbs was bone-marrow suppression. The doses to the bone marrow, resulting from the form of therapy, were calculated but showed no direct correlation with WHO grade 3/4 toxicity. Doses to the ventricular lining were also calculated, but due to the complex geometry of the compartment, calculation of potential tumour doses was not practicable.

Duke Scholars

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

August 19, 1992

Volume

52

Issue

1

Start / End Page

38 / 43

Location

United States

Related Subject Headings

  • Radioimmunotherapy
  • Radiation Dosage
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Meningitis
  • Meningeal Neoplasms
  • Iodine Radioisotopes
  • Injections, Spinal
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moseley, R. P., Papanastassiou, V., Zalutsky, M. R., Ashpole, R. D., Evans, S., Bigner, D. D., & Kemshead, J. T. (1992). Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer, 52(1), 38–43. https://doi.org/10.1002/ijc.2910520109
Moseley, R. P., V. Papanastassiou, M. R. Zalutsky, R. D. Ashpole, S. Evans, D. D. Bigner, and J. T. Kemshead. “Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.Int J Cancer 52, no. 1 (August 19, 1992): 38–43. https://doi.org/10.1002/ijc.2910520109.
Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, et al. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer. 1992 Aug 19;52(1):38–43.
Moseley, R. P., et al. “Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.Int J Cancer, vol. 52, no. 1, Aug. 1992, pp. 38–43. Pubmed, doi:10.1002/ijc.2910520109.
Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, Kemshead JT. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer. 1992 Aug 19;52(1):38–43.
Journal cover image

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

August 19, 1992

Volume

52

Issue

1

Start / End Page

38 / 43

Location

United States

Related Subject Headings

  • Radioimmunotherapy
  • Radiation Dosage
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Meningitis
  • Meningeal Neoplasms
  • Iodine Radioisotopes
  • Injections, Spinal
  • Humans